Neuphoria Therapeutics Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Neuphoria Therapeutics stock has a target of 21, which predicts an increase of 330.33% from the current stock price of 4.88.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$21	$21	$21	$21
Change	+330.33%	+330.33%	+330.33%	+330.33%

Analyst Ratings

According to 1 stock analyst, the rating for Neuphoria Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '25
Strong Buy	1
Buy	0
Hold	0
Sell	0
Strong Sell	0
Total	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Joseph Pantginis HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $8 → $21	Strong Buy	Maintains	$8 → $21	+330.33%	Feb 4, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

1.96M

EPS This Year

-11.73

from -0.01

EPS Next Year

-0.70

from -11.73

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2025
Period Ending	Jun 30, 2020	Jun 30, 2021	Jun 30, 2022	Jun 30, 2023	Jun 30, 2024	Jun 30, 2025	Jun 30, 2025
Revenue	2.99M	928.07K	6.06M	-	-	-	1.96M
Revenue Growth	-59.37%	-68.98%	552.46%	-	-	-	-
EPS	-0.01	-0.01	-0.02	-0.01	-0.01	-11.73	-0.70
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	3	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025
High	2.0M
Avg	2.0M
Low	1.9M

Revenue Growth

Revenue Growth	2025
High	-
Avg	-
Low	-

EPS Forecast

EPS	2025
High	-0.44
Avg	-0.70
Low	-0.94

EPS Growth

EPS Growth	2025
High	-
Avg	-
Low	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.